Clinic Software← All companies
StageSeries A (Later Stage)
Raised$11.8M
Founded2021
Employees2
LocationDurham, NC
About
Clinical stage drug development company
Product
- Value proposition
- Developing novel therapeutics for metabolic and gastrointestinal diseases, including post bariatric hypoglycemia and gastroparesis.
Founders
- James Green
Products
mizagliflozin (lead compound)
Key features
oral small-molecule inhibitor of SGLT1reduces postprandial glucose absorptionreduces insulin and GIP secretion
Technologies
SGLT1 inhibitorsmall molecule drug candidate
Target conditions
post bariatric hypoglycemiagastroparesisobesity
Investors
Kissei Pharmaceuticals, Ltd.
News
- Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference · 2025-04-15T14:45:00.000Z
- Vogenx has filed a notice of an exempt offering of securities to raise $5 Million in New Funding. - intelligence360 · 2026-02-02T19:23:27.000Z
- S-1 - SEC.gov · 2024-08-23T00:00:00.000Z
- Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference · 2025-04-15T18:45:00.000Z
- 10-K - SEC.gov · 2025-03-17T00:00:00.000Z
- Vogenx, Inc. to Present Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2025 Annual Conference · 2025-04-15T18:57:39.000Z
